226 related articles for article (PubMed ID: 15517700)
41. Conjunctival papilloma: features and outcomes based on age at initial examination.
Kaliki S; Arepalli S; Shields CL; Klein K; Sun H; Hysenj E; Lally SE; Shields JA
JAMA Ophthalmol; 2013 May; 131(5):585-93. PubMed ID: 23538642
[TBL] [Abstract][Full Text] [Related]
42. Adjuvant drug strategies in the treatment of recurrent respiratory papillomatosis.
Avidano MA; Singleton GT
Otolaryngol Head Neck Surg; 1995 Feb; 112(2):197-202. PubMed ID: 7530830
[TBL] [Abstract][Full Text] [Related]
43. Long-term response of recurrent respiratory papillomatosis to treatment with lymphoblastoid interferon alfa-N1. Papilloma Study Group.
Leventhal BG; Kashima HK; Mounts P; Thurmond L; Chapman S; Buckley S; Wold D
N Engl J Med; 1991 Aug; 325(9):613-7. PubMed ID: 1861694
[TBL] [Abstract][Full Text] [Related]
44. Recombinant human interferon alpha-2b (rh IFN alpha-2b) therapy for steroid resistant idiopathic thrombocytopenic purpura (ITP).
Fujimura K; Takafuta T; Kuriya S; Abe T; Akatsuka J; Yasunaga K; Uchida T; Kawakita M; Kitamura K; Nomura T; Kuramoto A
Am J Hematol; 1996 Jan; 51(1):37-44. PubMed ID: 8571936
[TBL] [Abstract][Full Text] [Related]
45. 5-Fluorouracil-interferon-alpha 2b adjuvant treatment of Dukes C colorectal cancer.
Frasci G; Leone F; Monaco M; Cremone L; Sapio U; Faiella F; Espinosa A; Persico G
Dis Colon Rectum; 1994 Jul; 37(7):643-50. PubMed ID: 8026229
[TBL] [Abstract][Full Text] [Related]
46. Pharmacotherapy of recurrent respiratory papillomatosis.
Kimberlin DW
Expert Opin Pharmacother; 2002 Aug; 3(8):1091-9. PubMed ID: 12150688
[TBL] [Abstract][Full Text] [Related]
47. Combined CO2-laser and alfa recombinant interferon treatment in five children with juvenile laryngeal papillomatosis.
Mattot M; Ninane J; Hamoir M; Moulin D; Mustin V; Vermylen C; Cornu G
Acta Clin Belg; 1990; 45(3):158-63. PubMed ID: 2166413
[TBL] [Abstract][Full Text] [Related]
48. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
[TBL] [Abstract][Full Text] [Related]
49. Regression of infancy hemangiomas with recombinant IFN-alpha 2b.
Garmendía G; Miranda N; Borroso S; Longchong M; Martínez E; Ferrero J; Porrero P; López-Saura P
J Interferon Cytokine Res; 2001 Jan; 21(1):31-8. PubMed ID: 11177578
[TBL] [Abstract][Full Text] [Related]
50. [Assessment of the formation of interferon neutralizing antibodies and their influence on the effectiveness of interferon therapy in children with juvenile respiratory papillomatosis].
Nurmukhametov RKh; Onufrieva EK; Soldatskiĭ IuL; Mezentseva MV; Kas'ianova NV; Tsvetnova MV; Kol'tsov VD
Vestn Otorinolaringol; 2000; (4):22-5. PubMed ID: 11011574
[TBL] [Abstract][Full Text] [Related]
51. Treatment of Adamantiades-Behçet disease with systemic interferon alfa.
Zouboulis CC; Orfanos CE
Arch Dermatol; 1998 Aug; 134(8):1010-6. PubMed ID: 9722733
[TBL] [Abstract][Full Text] [Related]
52. Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma.
Navid F; Herzog CE; Sandoval J; Daryani VM; Stewart CF; Gattuso J; Mandrell B; Phipps S; Chemaitilly W; Sykes A; Davidoff AM; Shulkin BL; Bahrami A; Furman WL; Mao S; Wu J; Schiff D; Rao B; Pappo A
Pediatr Blood Cancer; 2016 Jul; 63(7):1207-13. PubMed ID: 27038395
[TBL] [Abstract][Full Text] [Related]
53. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
[TBL] [Abstract][Full Text] [Related]
54. Can zinc be an adjuvant therapy for juvenile onset recurrent respiratory papillomatosis?
Bitar M; Baz R; Fuleihan N; Muallem M
Int J Pediatr Otorhinolaryngol; 2007 Aug; 71(8):1163-73. PubMed ID: 17560665
[TBL] [Abstract][Full Text] [Related]
55. [Results of long-term leukocyte interferon (alpha IFN) therapy using an individually determined dose schedule in recurrent laryngeal papillomatosis].
Gerein V; Lodemann E; Bell G; von Ilberg C; Kornhuber B
Klin Padiatr; 1987; 199(3):224-9. PubMed ID: 3114545
[TBL] [Abstract][Full Text] [Related]
56. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
57. Stepped-dose protocol of cidofovir therapy in recurrent respiratory papillomatosis in children.
Akst LM; Lee W; Discolo C; Knott D; Younes A; Koltai PJ
Arch Otolaryngol Head Neck Surg; 2003 Aug; 129(8):841-6. PubMed ID: 12925342
[TBL] [Abstract][Full Text] [Related]
58. [The relationship between tracheotomy and intra-tracheal papilloma progression in children].
Chen X; Liu D
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2000 Oct; 35(5):384-6. PubMed ID: 12768745
[TBL] [Abstract][Full Text] [Related]
59. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
[TBL] [Abstract][Full Text] [Related]
60. Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.
Zeuzem S; Yoshida EM; Benhamou Y; Pianko S; Bain VG; Shouval D; Flisiak R; Rehak V; Grigorescu M; Kaita K; Cronin PW; Pulkstenis E; Subramanian GM; McHutchison JG
Hepatology; 2008 Aug; 48(2):407-17. PubMed ID: 18666223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
